KRTX

Karuna Therapeutics, Inc. [KRTX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

KRTX Stock Summary

Top 10 Correlated ETFs

KRTX


Top 10 Correlated Stocks

KRTX


In the News

12:11 29 Mar 2024 KRTX

Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout

Karuna's (KRTX) fourth-quarter 2023 earnings and revenues miss estimates. The company is set to be acquired by Bristol Myers.

02:17 29 Mar 2024 KRTX

Bullish Continuation in '24? 3 Market Areas to Watch

Will stocks continue into 2024? Stock Strategist Andrew Rocco shares his prediction and unveils 3 important market areas to monitor.

06:47 29 Mar 2024 KRTX

Yes Virginia, There Is a Santa Claus Rally

The Russell is up an astounding +26% from late October, largely thanks to signaled interest rate cuts from the Fed in 2024.

12:46 29 Mar 2024 KRTX

Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers

Bristol Myers (BMY) is set to acquire Karuna (KRTX) for $330 per share. This transaction is expected to close in the first half of 2024.

04:10 29 Mar 2024 KRTX

Bristol-Myers buying Karuna signals a biotech boom ahead: Jefferies

Karuna Therapeutics Inc (NASDAQ: KRTX) ended nearly 50% up on Friday after Bristol-Myers Squibb Co (NYSE: BMY) said it will buy the biopharmaceutical firm for $14 billion.

06:29 29 Mar 2024 KRTX

Biotech boom ahead in 2024, top Jefferies analyst predicts on heels of Bristol Meyers-Karuna deal

Michael Yee, Jefferies Senior Biotech Analyst, joins 'Fast Money' to talk a possible boom ahead for the biotech sector.

01:27 29 Mar 2024 KRTX

Bristol Myers Squibb to buy Karuna Therapeutics for $14 billion in cash

Stephanie Link and Jim Lebenthal join 'Halftime Report' to discuss Bristol Myers Squibb's latest announcement to buy Karuna Therapeutics for $14 billion.

01:14 29 Mar 2024 KRTX

Bristol Myers Squibb buys neurological drug developer Karuna Therapeutics in $14B deal

Shares of biopharmaceutical company Karuna Therapeutics skyrocketed more than 47% Friday morning after giant Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) announced a deal to acquire the company in a $14 billion cash deal.  The agreement valued Karuna at $330 per share.

12:45 29 Mar 2024 KRTX

Midday Movers: Karuna Jumps on Deal With Bristol Myers Squibb, Nike Falls on Sales Outlook

U.S. equities headed into the long holiday weekend with gains at midday, amid a broad-based rally fueled by enthusiasm over the possibility of several Fed interest rate cuts next year. The Dow, S&P 500, and Nasdaq were all up.

12:40 29 Mar 2024 KRTX

Bristol Myers Squibb Boosts Its Neuroscience Reach With $14 Billion Karuna Deal

Karuna Therapeutics (KRTX) shares skyrocketed over 46% after Bristol Myers Squibb (BMY) said it would buy the biopharmaceutical firm for $14 billion to expand its neuroscience portfolio.

KRTX Financial details

Company Rating
Neutral
Market Cap
12.6B
Income
-422.19M
Revenue
654K
Book val./share
33.2
Cash/share
33.42
Dividend
-
Dividend %
-
Employees
339
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-31.08
Forward P/E
-40.08
PEG
-10.25
P/S
2025.83
P/B
9.04
P/C
9.87
P/FCF
-48.99
Quick Ratio
27.35
Current Ratio
27.88
Debt / Equity
0.01
LT Debt / Equity
0.01
-
-
EPS (TTM)
-11.39
EPS next Y
-8.23
EPS next Q
-2.85
EPS this Y
34.21%
EPS next Y
-27.75%
EPS next 5Y
-350.59%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-4.75%
-
-
-
-
SMA20
2.19%
SMA50
3.16%
SMA100
91.76%
Inst Own
69.1%
Inst Trans
0.65%
ROA
-28%
ROE
-29%
ROC
-0.34%
Gross Margin
100%
Oper. Margin
-7590%
Profit Margin
-6483%
Payout
-
Shs Outstand
38.2M
Shs Float
36.27M
-
-
-
-
Target Price
257.5
52W Range
158.375-329.99
52W High
+0.25%
52W Low
+108.75%
RSI
77
Rel Volume
1.32
Avg Volume
971.83K
Volume
1.28M
Perf Week
3.33%
Perf Month
4.44%
Perf Quarter
96.68%
Perf Half Y
100.31%
-
-
-
-
Beta
1.149
-
-
Volatility
3.46%, 4.79%
Prev Close
0%
Price
329.83
Change
0%

KRTX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
001.270.340.02
Net income per share
-3.75-2.59-4.94-8.74-11.73
Operating cash flow per share
-2.59-2.64-3.46-7.21-10.44
Free cash flow per share
-2.6-2.66-3.57-7.24-10.52
Cash per share
32.5612.1916.9535.5434.17
Book value per share
32.6112.8217.2335.6133.94
Tangible book value per share
32.6112.8217.2335.6133.94
Share holders equity per share
32.6112.8217.2335.6133.94
Interest debt per share
0.10.10.260.620.45
Market cap
900.93M2.69B3.82B6.22B11.7B
Enterprise value
692.21M2.64B3.62B5.97B11.53B
P/E ratio
-20.09-39.19-26.54-22.49-26.97
Price to sales ratio
00103.27584.2917.89K
POCF ratio
-29.13-38.46-37.84-27.26-30.32
PFCF ratio
-29.03-38.23-36.72-27.15-30.09
P/B Ratio
2.317.937.65.529.33
PTB ratio
2.317.937.65.529.33
EV to sales
0097.87561.4517.63K
Enterprise value over EBITDA
-16.14-38.48-25.27-20.62-23.38
EV to operating cash flow
-22.38-37.74-35.86-26.19-29.88
EV to free cash flow
-22.3-37.51-34.8-26.09-29.66
Earnings yield
-0.05-0.03-0.04-0.04-0.04
Free cash flow yield
-0.03-0.03-0.03-0.04-0.03
Debt to equity
00.010.0100.01
Debt to assets
00.010.0100.01
Net debt to EBITDA
4.870.741.390.840.34
Current ratio
132.7650.2825.5934.0219.31
Interest coverage
-48.0500-20.430
Income quality
0.71.020.70.830.89
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
001.427.15200.81
Research and developement to revenue
003.4721.08556.73
Intangibles to total assets
00000
Capex to operating cash flow
00.010.0300.01
Capex to revenue
00-0.08-0.09-4.46
Capex to depreciation
-1.98-2.89-6.07-0.82-1.71
Stock based compensation to revenue
000.814.46114.07
Graham number
52.4527.3443.7483.6694.66
ROIC
-0.12-0.21-0.28-0.26-0.38
Return on tangible assets
-0.11-0.2-0.27-0.24-0.32
Graham Net
32.311.8616.4834.8132.49
Working capital
389.75M337.75M497.12M1.12B1.25B
Tangible asset value
389.92M339.74M503.95M1.13B1.25B
Net current asset value
389.6M335.91M491.69M1.12B1.23B
Invested capital
00.010.0100.01
Average receivables
00875K903.5K2.48M
Average payables
408K706K1.4M2.16M4.58M
Average inventory
0010.44M24.61M30.58M
Days sales outstanding
0017.281.962.73K
Days payables outstanding
3.44K2.18K1.4K780.881.46K
Days of inventory on hand
0015.07K9.3K7.04K
Receivables turnover
0021.12186.610.13
Payables turnover
0.110.170.260.470.25
Inventory turnover
000.020.040.05
ROE
-0.12-0.2-0.29-0.25-0.35
Capex per share
-0.01-0.02-0.11-0.03-0.08

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.150.02000
Net income per share
-2.22-2.47-2.75-3.16-3.01
Operating cash flow per share
-2.29-2.89-1.71-2.92-2.94
Free cash flow per share
-2.3-2.91-1.73-2.94-2.96
Cash per share
32.6742.3138.2835.5933.42
Book value per share
32.7342.7637.8335.0833.2
Tangible book value per share
32.7342.7637.8335.0833.2
Share holders equity per share
32.7342.7637.8335.0833.2
Interest debt per share
0.43-0.190.420.410.75
Market cap
6.76B6.32B8.14B6.37B11.96B
Enterprise value
6.52B5.76B7.89B6.2B11.79B
P/E ratio
-22.18-18.36-19.72-13.37-26.26
Price to sales ratio
1.28K9.67K000
POCF ratio
-85.84-62.82-126.88-57.94-107.67
PFCF ratio
-85.53-62.37-125.36-57.61-106.9
P/B Ratio
64.255.734.829.53
PTB ratio
64.255.734.829.53
EV to sales
1.23K8.81K000
Enterprise value over EBITDA
-76.65-52.84-65.8-45.54-91.29
EV to operating cash flow
-82.76-57.27-123.01-56.4-106.15
EV to free cash flow
-82.45-56.87-121.55-56.08-105.39
Earnings yield
-0.01-0.01-0.01-0.02-0.01
Free cash flow yield
-0.01-0.02-0.01-0.02-0.01
Debt to equity
000.010.010.01
Debt to assets
000.010.010.01
Net debt to EBITDA
2.865.122.071.241.31
Current ratio
34.0259.7437.6127.8819.31
Interest coverage
-8.899.4900-11.28
Income quality
1.031.030.620.920.98
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
4.6137.08000
Research and developement to revenue
12.51130.68000
Intangibles to total assets
00000
Capex to operating cash flow
00.010.010.010.01
Capex to revenue
-0.05-1.09000
Capex to depreciation
-0.95-2.18-1.65-1.37-1.79
Stock based compensation to revenue
2.423.71000
Graham number
40.3948.7848.3749.9547.44
ROIC
-0.08-0.06-0.07-0.09-0.1
Return on tangible assets
-0.07-0.06-0.07-0.09-0.09
Graham Net
3241.536.8834.1331.79
Working capital
1.12B1.48B1.41B1.32B1.25B
Tangible asset value
1.13B1.49B1.42B1.32B1.25B
Net current asset value
1.12B1.48B1.4B1.3B1.23B
Invested capital
000.010.010.01
Average receivables
69K28.5K02.45M4.9M
Average payables
9.05M1.43M789K2.02M4.86M
Average inventory
26.6M14.16M03.75M20.16M
Days sales outstanding
0.970000
Days payables outstanding
702131.01211.47577.531.37K
Days of inventory on hand
8.36K001.47K6.61K
Receivables turnover
92.60000
Payables turnover
0.130.690.430.160.07
Inventory turnover
0.01000.060.01
ROE
-0.07-0.06-0.07-0.09-0.09
Capex per share
-0.01-0.02-0.02-0.02-0.02

KRTX Frequently Asked Questions

What is Karuna Therapeutics, Inc. stock symbol ?

Karuna Therapeutics, Inc. is a US stock , located in Boston of Ma and trading under the symbol KRTX

Is Karuna Therapeutics, Inc. buy or a sell ?

6 stock analysts have 6 predictions with a medium analyst target price of $257.5. The lowest prediction is $150 and the highest is $330

What is KRTX stock prediction ?

What is Karuna Therapeutics, Inc. stock quote today ?

Karuna Therapeutics, Inc. stock price is $329.83 today.

Is Karuna Therapeutics, Inc. stock public?

Yes, Karuna Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap